Abstract

Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with

Key Points
Prolonged ruxolitinib administration after allogeneic HCT is associated with low rates of clinically significant chronic GVHD.

Cyclophosphamide plus cyclosporin, a calcineurin inhibitor, significantly improved graft-vs-host disease (GVHD)–free relapse-free survival (RFS) compared with standard prophylaxis in patients with aggressive blood cancers who are undergoing stem cell transplant from a matched related blood stem cell donor with reduced-intensity or myeloablative conditioning, according to results from the phase 3 BM12 CAST trial (ACTRN12618000505202) presented during the European Hematology Association 2025 Congress.1

ABSTRACT
Background
Elevated blood counts in polycythemia vera (PV) are associated with increased thrombotic risk, which contributes to morbidity and mortality.

Research design and methods
This retrospective study describes treatment patterns and blood count control in patients with PV managed at community oncology practices (January 2014–February 2023; Integra Precision Q database).

Amer Zeidan, MBBS, MHS, is professor of internal medicine at Yale School of Medicine in New Haven, Connecticut. He is also the chief of the Division of Hematologic Malignancies at Yale Cancer Center, New Haven.

Dr. Zeidan spoke with Blood Cancers Today about the phase 1/2 BEXMAB study, which was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, recently held in Chicago, Illinois, and will be presented at the European Hematology Association (EHA) 2025 Congress in Milan, Italy.

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly identified monogenic disorder with symptoms including recurrent fever, skin involvement, pulmonary infiltrates, systemic vasculitis, and chondritis.1 Notably, 25-50% of patients also have myelodysplastic syndrome (MDS). VEXAS syndrome often requires high-dose steroids and is resistant to standard immunomodulatory agents.